Trial Profile
Efficacy of Sofosbuvir plus Daclatasvir with or without ribavirin and velpatasivr/sofosbuvir with or without ribavirin in genotype 2 and 3 HCV-infected patients: An observational retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 Sep 2018 Results published in the Journal of Hepatology
- 19 Jul 2018 New trial record
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018